By: IPP Bureau
Last updated : October 22, 2021 10:20 pm
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
For the quarter ended September 30, 2021 (Q2 FY2022), the company's net profit was Rs 142.84 crore, against Rs 224.03 crore in the corresponding quarter of the previous year (YoY) and Rs 160.56 crore in the previous quarter (QoQ).
For the six months ended September 30, 2021 (Half Year Ended FY 2022), the company's total income was Rs 3,300.44 crore, against Rs 2754.78 crore in the previous year (YoY) (Half Year Ended FY 2021).
The net profit was at Rs 303.40 crore for the six months ended September 30, 2021 (Half Year Ended FY 2022), compared to Rs 312.04 crore in the previous year (YoY) (Half Year Ended FY 2021).
Commenting on the company’s performance, Shyam S Bhartia, Chairman and Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Pharmova said: “The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment. In the Pharmaceuticals segment, while Radiopharma, Allergy and CMO businesses reported growth on a YoY basis, the API business’ performance was lower on a higher base last year and the Generics business witnessed headwinds due to temporary pricing pressure in the US market. The Generics business was also affected during the quarter by the Import Alert at the Roorkee plant and by the impact of the industry-wide impurity issue in certain sartan products that led to lower sales and some product withdrawal.’’
They further added, ``In our Contract Research and Development Services business, we witnessed strong growth both YoY and sequentially driven by continued strong demand from our customers for our Drug Discovery Services. In the Proprietary Novel Drugs business, our plans are on track to take one program to the clinical stage by end of this financial year.’’
They also added, ``During H1’FY22, we grew our revenues by 20% YoY and improved our EBITDA margins by 2.44% vs. H1’FY21 due to recovery in Radiopharma business and strong performance in Allergy Immunotherapy, CMO, API and Contract Research businesses.
I would like to mention that over the medium term, we have very strong growth levers in all our businesses. To drive growth in these businesses, the company will continue to invest accordingly.”